Skip to main content

Table 3 Clinical characteristics of DM patients with versus without anti-Mi-2

From: Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara

  All DM
Number = 66
Mexico City DM
Number = 46
Guadalajara DM
Number = 20
  Anti-Mi-2
(+)
Anti-Mi-2
(-)
Anti-Mi-2
(+)
Anti-Mi-2
(-)
Anti-Mi-2
(+)
Anti-Mi-2
(-)
Number 30 36 27 19 3 17
Age 41.3 44.1 42.0 50.3 34.7 37.2
(mean ± SD) ± 14.2 ± 16.3 ± 14.7a ± 15.1a, b ± 4.5 ± 15.3b
% male 37% 22% 33% 26% 67% 18%
Shawl sign 86%c 61%c 85% 78%d 100% 40%d
Heliotrope 74% 79% 71% 89% 100% 69%
Gottrön 78% 74% 79% 78% 67% 69%
Malignancy 0% 6% 0% 11% 0% 0%
Fever 30% 25% 25% 28% 67% 21%
Calcinosis 7% 9% 4% 5% 33% 13%
ILD 7% 9% 4% 17% 50% 0%
Initial CPK IU/L
(mean ± SD)
5,369
± 4,124e
2,860
± 5,183e
4,800
± 3,111f
3,502
± 6,068f, g
NA 1,808
± 3,475g
Initial CPK
< 200 IU/L
0%h 34%h 0%i 22%i, j NA 55%j
Initial CPK
> 1,000 IU/L
100%k 52%k 100%l 67%l, m NA 27%m
Initial CPK
> 5,000 IU/L
54%n 14%n 52%o 17%o NA 9%
Last CPK
> 500 IU/L
37%p 7%p 15% 0% NA 18%
Last CPK
< 200 IU/L
45% 69% 45% 67% NA 73%
  1. aP < 0.05; bP < 0.005; cP < 0.05; dP < 0.05; eP < 0.0005; fP < 0.01; gnot significant; hP < 0.005; iP < 0.05; jP = 0.11; kP < 0.0001; lP < 0.005; mP = 0.06; nP < 0.005; 15, oP < 0.05; pP = 0.095. CPK, creatine phosphokinase; DM, dermatomyositis; ILD, interstitial lung disease; NA, not applicable (due to small numbers).